A carregar...
Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments
Recently, NICE was given the task of governing the Cancer Drug Fund (CDF) in the UK as the latter was criticized for allowing too many insufficiently tested drugs to be covered [1, 2]. The CDF was initiated in 2012, but immediately received criticism from several health economists because of the rat...
Na minha lista:
| Publicado no: | Ecancermedicalscience |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cancer Intelligence
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5606291/ https://ncbi.nlm.nih.gov/pubmed/28955404 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2017.ed71 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|